Other substances

Opaganib

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
4
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Compassionate Use of Opaganib For Patients with Severe COVID-19
Severe severity Preprint 		Patients Jun/23/2020

AI-suggested references

Link Publication date
Comparative MD Study of Inhibitory Activity of Opaganib and Adamantane-Isothiourea Derivatives toward COVID-19 Main Protease Mpro
Mar/14/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04502069 Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen Withdrawn Phase 1|Phase 2 Aug/01/2020 Jun/01/2021
  • Alternative id - ABC-112
  • Interventions - Drug: Opaganib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Shaare Zedek Medical Center, Jerusalem, Israel
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to breathing room air|Adverse Event Grading and Coding
NCT04435106 Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19) Completed Apr/03/2020 May/15/2020
  • Alternative id - 0123-20- SZMC
  • Interventions - Drug: Opaganib|Drug: Standard of Care
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Shaare-Zedek Medical Center, Jerusalem, Israel
  • Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
  • Enrollment - 23
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Measure the time to weaning from high-flow nasal cannula|Measure the time to breathing ambient (room) air|Measure change in lymphocyte count|Measure change in C-reactive protein
NCT04467840 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia Completed Phase 2|Phase 3 Aug/21/2020 Jul/18/2021
  • Alternative id - ABC-201
  • Interventions - Drug: Opaganib|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ABC-201 Site 901, Detroit, Michigan, United States|ABC-201 Site 408, Belo Horizonte, Brazil|ABC-201 Site 411, Belo Horizonte, Brazil|ABC-201 Site 405, Joinville, Brazil|ABC-201 Site 404, Paraná, Brazil|ABC-201 Site 410, Passo Fundo, Brazil|ABC-201 Site 409, Porto Alegre, Brazil|ABC-201 Site 401, Sao Paulo, Brazil|ABC-201 Site 402, São Bernardo Do Campo, Brazil|ABC-201 Site 403, São Paulo, Brazil|ABC-201 Site 407, Tubarão, Brazil|ABC-201 Site 604, Medellín, Antioquia, Colombia|ABC-201 Site 603, Bogotá, Colombia|ABC-201 Site 605, Cundinamarca, Colombia|ABC-201 Site 602, Medellín, Colombia|ABC-201 Site 601, Santiago de Cali, Colombia|ABC-201 Site 708, Ashkelon, Ashketon, Israel|ABC-201 Site 702, Ashdod, Israel|ABC-201 Site 704, Holon, Israel|ABC-201 Site 701, Jerusalem, Israel|ABC-201,Site 709, Kfar Saba, Israel|ABC-201 Site 705, Nahariya, Israel|ABC-201 Site 706, Nazareth, Israel|ABC-201 Site 703, Safed, Israel|ABC-201 Site 203, Alessandria, Italy|ABC-201 Site 201, Lecco, Italy|ABC-201 Site 202, Milano, Italy|ABC-201 Site 204, Torino, Italy|ABC-201 Site 501, Mexico City, Mexico|ABC-201 Site 503, Sinaloa, Mexico|ABC-201 Site 655, Lima, Peru|ABC-201 Site 303, Bolesławiec, Poland|ABC-201 Site 306, Katowice, Poland|ABC-201 Site 304, Koszalin, Poland|ABC-201 Site 307, Lublin, Poland|ABC-201 Site 302, Ostróda, Poland|ABC-201 Site 301, Racibórz, Poland|ABC-201 Site 305, Wrocław, Poland|ABC-201 Site 308, Łódź, Poland|ABC-201 Site 110, Barnaul, Russian Federation|ABC-201 Site 122, Kirovsk, Russian Federation|ABC-201 Site 101, Moscow, Russian Federation|ABC-201 Site 132, Moscow, Russian Federation|ABC-201 Site 120, Murmansk, Russian Federation|ABC-201 Site 103, Ryazan, Russian Federation|ABC-201 Site 114, Ryazan, Russian Federation|ABC-201 Site 129, Saint Petersburg, Russian Federation|ABC-201 Site 108, Saratov, Russian Federation|ABC-201 Site 102, Smolensk, Russian Federation|ABC-201 Site 109, St Petersburg, Russian Federation|ABC-201 Site 111, St Petersburg, Russian Federation|ABC-201 Site 104, Tver, Russian Federation|ABC-201 Site 118, Volgograd, Russian Federation|ABC-201 Site 112, Yaroslavl, Russian Federation|ABC-201 Site 253, Antrim, United Kingdom|ABC-201 Site 251, Gillingham, United Kingdom|ABC-201 Site 252, Taunton, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 475
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Supplemental oxygen requirement|WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0|Time to recovery as defined by improvement to a score of 3 or less on the WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0|Time to low oxygen flow via nasal cannula|Time to discharge from hospital|Requiring intubation and mechanical ventilation by Day 42|Time to two consecutive negative swabs for SARS-CoV-2 at day 14|Negative swabs for SARS-CoV-2 at day 14|Fever|Mortality
NCT04414618 A Study of Opaganib in Coronavirus Disease 2019 Pneumonia Completed Phase 2 Jul/02/2020 Dec/23/2020
  • Alternative id - ABC-110
  • Interventions - Drug: Opaganib|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - HonorHealth Research Institute, Scottsdale, Arizona, United States|Miami Cancer Institute, Miami, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Albany Medical Center, Albany, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Memorial Herman Southeast Hospital, Houston, Texas, United States|Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States|Ziv Medical Center, Safed, Israel
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 42
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Measurement of the Change in Oxygen Requirement From Baseline|Measurement of Time to the Reduction in Oxygen Requirement.|The Percentage of Subjects no Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14|Time to Negative Swabs for SARS-CoV-2 by PCR Post Treatment|The Percentage of Subjects With at Least Two Consecutive Negative Swabs for SARS-CoV-2 by PCR at Day 14|Intubation and Mechanical Ventilation Requirements|Evaluation of the Time to Intubation and Mechanical Ventilation|Evaluation the Proportion of Patients, With at Least One Measurement of Fever at Baseline Who Are Afebrile at Day 14|Evaluation of Mortality 30 Days Post-baseline
Export (.csv)